PT Central Proteina Prima Tbk Logo

PT Central Proteina Prima Tbk

CPRO.JK

(2.8)
Stock Price

50 IDR

5.06% ROA

10.05% ROE

8.45x PER

Market Cap.

2.978.620.000.000 IDR

57.28% DER

0% Yield

3.88% NPM

PT Central Proteina Prima Tbk Stock Analysis

PT Central Proteina Prima Tbk Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

PT Central Proteina Prima Tbk Fundamental Stock Analysis
# Analysis Rating
1 PBV

With a remarkably low PBV ratio (0.93x), the stock offers substantial upside potential at a bargain price.

2 Revenue Growth

With a track record of consistent revenue growth in the past five years, this company presents a compelling opportunity.

3 Assets Growth

Over the past five years, this company's revenue has consistently increased, demonstrating a robust financial performance that makes it an appealing opportunity.

4 ROE

The stock's ROE falls within an average range (12.59%), demonstrating satisfactory profitability and efficiency in utilizing shareholders' equity.

5 ROA

The stock's ROA (6.07%) indicates that it's doing well in making money from the things it owns. This makes it a good option to invest and make consistent profits.

6 DER

The stock maintains a fair debt to equity ratio (59%), indicating a reasonable balance between the money it owes and the ownership it possesses.

7 Graham Number

The Graham number analysis indicates that this company's stock price is likely undervalued, raising prospects for a favorable investment opportunity.

8 Buffet Intrinsic Value

The company's stock shows potential as it is undervalued (1.358) according to Warren Buffett's formula, indicating that its intrinsic value exceeds the market price.

9 Net Profit Growth

The net profit of this company has shown no signs of growth over the last five years, suggesting limited profitability and making it a less attractive investment opportunity.

10 Dividend Growth

The company's dividend growth has shown no improvement in the past three years, making it a less attractive investment option for those seeking increasing returns.

11 Dividend

The company has not distributed any dividends in the past three years, which may raise concerns for investors looking for regular income from their investments.

PT Central Proteina Prima Tbk Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

PT Central Proteina Prima Tbk Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Sell
2 MACD Buy
3 RSI Hold
4 Stoch RSI Hold

PT Central Proteina Prima Tbk Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

PT Central Proteina Prima Tbk Revenue
Year Revenue Growth
2007 6.123.044.000.000
2008 8.169.928.000.000 25.05%
2009 6.832.754.000.000 -19.57%
2010 6.243.876.000.000 -9.43%
2011 7.529.439.000.000 17.07%
2012 6.835.813.000.000 -10.15%
2013 7.677.823.000.000 10.97%
2014 9.454.661.000.000 18.79%
2015 8.975.064.000.000 -5.34%
2016 8.597.208.000.000 -4.4%
2017 6.575.570.000.000 -30.74%
2018 7.390.580.000.000 11.03%
2019 7.175.764.000.000 -2.99%
2020 7.573.506.000.000 5.25%
2021 8.028.078.000.000 5.66%
2022 8.242.343.000.000 2.6%
2023 9.306.768.000.000 11.44%
2023 9.027.276.000.000 -3.1%
2024 8.837.008.000.000 -2.15%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

PT Central Proteina Prima Tbk Research and Development Expenses
Year Research and Development Expenses Growth
2007 0
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 2.203.000.000 100%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

PT Central Proteina Prima Tbk General and Administrative Expenses
Year General and Administrative Expenses Growth
2007 386.639.000.000
2008 538.504.000.000 28.2%
2009 576.570.000.000 6.6%
2010 539.637.000.000 -6.84%
2011 520.083.000.000 -3.76%
2012 107.171.000.000 -385.28%
2013 198.990.000.000 46.14%
2014 224.396.000.000 11.32%
2015 226.157.000.000 0.78%
2016 176.769.000.000 -27.94%
2017 133.549.000.000 -32.36%
2018 137.625.000.000 2.96%
2019 120.964.000.000 -13.77%
2020 100.351.000.000 -20.54%
2021 123.928.000.000 19.02%
2022 146.888.000.000 15.63%
2023 177.184.000.000 17.1%
2023 160.147.000.000 -10.64%
2024 138.556.000.000 -15.58%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

PT Central Proteina Prima Tbk EBITDA
Year EBITDA Growth
2007 134.278.000.000
2008 594.930.000.000 77.43%
2009 -187.673.000.000 417%
2010 -391.720.000.000 52.09%
2011 1.052.536.000.000 137.22%
2012 -118.832.000.000 985.73%
2013 -571.481.000.000 79.21%
2014 154.936.000.000 468.85%
2015 -182.209.000.000 185.03%
2016 -44.032.000.000 -313.81%
2017 -963.781.000.000 95.43%
2018 -91.256.000.000 -956.13%
2019 208.370.000.000 143.8%
2020 682.702.000.000 69.48%
2021 854.724.000.000 20.13%
2022 772.957.000.000 -10.58%
2023 782.240.000.000 1.19%
2023 897.926.000.000 12.88%
2024 876.144.000.000 -2.49%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

PT Central Proteina Prima Tbk Gross Profit
Year Gross Profit Growth
2007 1.099.914.000.000
2008 1.543.879.000.000 28.76%
2009 836.116.000.000 -84.65%
2010 659.672.000.000 -26.75%
2011 693.678.000.000 4.9%
2012 965.773.000.000 28.17%
2013 1.144.870.000.000 15.64%
2014 1.457.767.000.000 21.46%
2015 1.461.228.000.000 0.24%
2016 1.422.954.000.000 -2.69%
2017 1.160.891.000.000 -22.57%
2018 1.234.632.000.000 5.97%
2019 1.341.700.000.000 7.98%
2020 1.345.503.000.000 0.28%
2021 1.494.905.000.000 9.99%
2022 1.644.703.000.000 9.11%
2023 1.825.364.000.000 9.9%
2023 1.628.255.000.000 -12.11%
2024 1.647.852.000.000 1.19%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

PT Central Proteina Prima Tbk Net Profit
Year Net Profit Growth
2007 358.413.000.000
2008 -407.182.000.000 188.02%
2009 -217.171.000.000 -87.49%
2010 -635.482.000.000 65.83%
2011 -2.036.125.000.000 68.79%
2012 -435.894.000.000 -367.11%
2013 1.200.315.000.000 136.31%
2014 -389.410.000.000 408.24%
2015 -1.200.383.000.000 67.56%
2016 -1.987.884.000.000 39.62%
2017 -2.636.278.000.000 24.6%
2018 1.722.582.000.000 253.04%
2019 -348.863.000.000 593.77%
2020 380.902.000.000 191.59%
2021 2.208.722.000.000 82.75%
2022 373.668.000.000 -491.09%
2023 376.256.000.000 0.69%
2023 401.468.000.000 6.28%
2024 317.352.000.000 -26.51%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

PT Central Proteina Prima Tbk Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2007 20
2008 -19 205.26%
2009 -5 -280%
2010 -16 66.67%
2011 -50 70%
2012 -11 -400%
2013 30 134.48%
2014 -10 422.22%
2015 -30 68.97%
2016 -49 40.82%
2017 -65 24.62%
2018 34 291.18%
2019 -6 780%
2020 6 183.33%
2021 37 83.78%
2022 6 -516.67%
2023 6 0%
2023 7 0%
2024 5 -20%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

PT Central Proteina Prima Tbk Free Cashflow
Year Free Cashflow Growth
2007 -3.774.615.000.000
2008 -1.905.035.000.000 -98.14%
2009 -178.935.000.000 -964.65%
2010 -16.364.000.000 -993.47%
2011 -151.802.000.000 89.22%
2012 -15.298.000.000 -892.3%
2013 -145.482.000.000 89.48%
2014 -129.210.000.000 -12.59%
2015 -229.309.000.000 43.65%
2016 232.350.000.000 198.69%
2017 -176.594.000.000 231.57%
2018 50.350.000.000 450.73%
2019 315.490.000.000 84.04%
2020 635.068.000.000 50.32%
2021 -73.084.000.000 968.96%
2022 118.655.000.000 161.59%
2023 206.327.000.000 42.49%
2023 -39.284.000.000 625.22%
2024 20.571.000.000 290.97%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

PT Central Proteina Prima Tbk Operating Cashflow
Year Operating Cashflow Growth
2007 -1.144.064.000.000
2008 -39.026.000.000 -2831.54%
2009 171.218.000.000 122.79%
2010 118.663.000.000 -44.29%
2011 -45.689.000.000 359.72%
2012 77.586.000.000 158.89%
2013 54.079.000.000 -43.47%
2014 22.363.000.000 -141.82%
2015 10.877.000.000 -105.6%
2016 307.083.000.000 96.46%
2017 -145.816.000.000 310.6%
2018 109.828.000.000 232.77%
2019 358.866.000.000 69.4%
2020 756.892.000.000 52.59%
2021 99.209.000.000 -662.93%
2022 284.210.000.000 65.09%
2023 323.485.000.000 12.14%
2023 -2.500.000.000 13039.4%
2024 82.455.000.000 103.03%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

PT Central Proteina Prima Tbk Capital Expenditure
Year Capital Expenditure Growth
2007 2.630.551.000.000
2008 1.866.009.000.000 -40.97%
2009 350.153.000.000 -432.91%
2010 135.027.000.000 -159.32%
2011 106.113.000.000 -27.25%
2012 92.884.000.000 -14.24%
2013 199.561.000.000 53.46%
2014 151.573.000.000 -31.66%
2015 240.186.000.000 36.89%
2016 74.733.000.000 -221.39%
2017 30.778.000.000 -142.81%
2018 59.478.000.000 48.25%
2019 43.376.000.000 -37.12%
2020 121.824.000.000 64.39%
2021 172.293.000.000 29.29%
2022 165.555.000.000 -4.07%
2023 117.158.000.000 -41.31%
2023 36.784.000.000 -218.5%
2024 61.884.000.000 40.56%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

PT Central Proteina Prima Tbk Equity
Year Equity Growth
2007 1.539.951.000.000
2008 3.352.858.000.000 54.07%
2009 3.220.190.000.000 -4.12%
2010 2.584.137.000.000 -24.61%
2011 545.914.000.000 -373.36%
2012 109.585.000.000 -398.16%
2013 1.307.622.000.000 91.62%
2014 917.715.000.000 -42.49%
2015 1.982.383.000.000 53.71%
2016 180.885.000.000 -995.94%
2017 -1.780.456.000.000 110.16%
2018 674.343.000.000 364.03%
2019 329.492.000.000 -104.66%
2020 707.584.000.000 53.43%
2021 2.861.207.000.000 75.27%
2022 3.181.832.000.000 10.08%
2023 3.500.595.000.000 9.11%
2023 3.419.703.000.000 -2.37%
2024 3.597.992.000.000 4.96%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

PT Central Proteina Prima Tbk Assets
Year Assets Growth
2007 7.794.496.000.000
2008 9.370.538.000.000 16.82%
2009 8.702.005.000.000 -7.68%
2010 8.433.444.000.000 -3.18%
2011 7.062.598.000.000 -19.41%
2012 7.128.870.000.000 0.93%
2013 7.179.387.000.000 0.7%
2014 7.086.117.000.000 -1.32%
2015 9.086.586.000.000 22.02%
2016 7.323.273.000.000 -24.08%
2017 7.006.675.000.000 -4.52%
2018 6.572.440.000.000 -6.61%
2019 6.000.259.000.000 -9.54%
2020 6.326.293.000.000 5.15%
2021 6.448.014.000.000 1.89%
2022 6.833.737.000.000 5.64%
2023 7.037.582.000.000 2.9%
2023 6.856.338.000.000 -2.64%
2024 6.971.599.000.000 1.65%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

PT Central Proteina Prima Tbk Liabilities
Year Liabilities Growth
2007 6.254.545.000.000
2008 6.017.680.000.000 -3.94%
2009 5.481.815.000.000 -9.78%
2010 5.849.307.000.000 6.28%
2011 6.516.684.000.000 10.24%
2012 7.019.285.000.000 7.16%
2013 5.871.765.000.000 -19.54%
2014 6.168.402.000.000 4.81%
2015 7.104.203.000.000 13.17%
2016 7.142.388.000.000 0.53%
2017 8.787.131.000.000 18.72%
2018 5.898.097.000.000 -48.98%
2019 5.670.767.000.000 -4.01%
2020 5.618.709.000.000 -0.93%
2021 3.586.807.000.000 -56.65%
2022 3.651.905.000.000 1.78%
2023 3.536.987.000.000 -3.25%
2023 3.436.635.000.000 -2.92%
2024 3.373.607.000.000 -1.87%

PT Central Proteina Prima Tbk Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
152.55
Net Income per Share
5.91
Price to Earning Ratio
8.45x
Price To Sales Ratio
0.33x
POCF Ratio
14.58
PFCF Ratio
564.45
Price to Book Ratio
0.83
EV to Sales
0.55
EV Over EBITDA
5.95
EV to Operating CashFlow
24.4
EV to FreeCashFlow
944.83
Earnings Yield
0.12
FreeCashFlow Yield
0
Market Cap
2.979 Bil.
Enterprise Value
4.986 Bil.
Graham Number
89.61
Graham NetNet
-32.77

Income Statement Metrics

Net Income per Share
5.91
Income Quality
0.58
ROE
0.1
Return On Assets
0.05
Return On Capital Employed
0.15
Net Income per EBT
0.77
EBT Per Ebit
0.62
Ebit per Revenue
0.08
Effective Tax Rate
0.23

Margins

Sales, General, & Administrative to Revenue
0.02
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.18
Operating Profit Margin
0.08
Pretax Profit Margin
0.05
Net Profit Margin
0.04

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
3.43
Free CashFlow per Share
0.09
Capex to Operating CashFlow
0.97
Capex to Revenue
0.02
Capex to Depreciation
1.33
Return on Invested Capital
0.1
Return on Tangible Assets
0.05
Days Sales Outstanding
30.83
Days Payables Outstanding
21.38
Days of Inventory on Hand
74.77
Receivables Turnover
11.84
Payables Turnover
17.08
Inventory Turnover
4.88
Capex per Share
3.34

Balance Sheet

Cash per Share
1,45
Book Value per Share
60,40
Tangible Book Value per Share
60.23
Shareholders Equity per Share
60.35
Interest Debt per Share
37.78
Debt to Equity
0.57
Debt to Assets
0.3
Net Debt to EBITDA
2.4
Current Ratio
1.11
Tangible Asset Value
3.588 Bil.
Net Current Asset Value
-932 Bil.
Invested Capital
4181672000000
Working Capital
241 Bil.
Intangibles to Total Assets
0
Average Receivables
805 Bil.
Average Payables
511 Bil.
Average Inventory
1502097000000
Debt to Market Cap
0.69

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

PT Central Proteina Prima Tbk Dividends
Year Dividends Growth

PT Central Proteina Prima Tbk Profile

About PT Central Proteina Prima Tbk

PT Central Proteina Prima Tbk, together with its subsidiaries, operates as an integrated aquaculture company in Indonesia and internationally. The company operates through Feeds, Food Products, and Others segments. It engages in the shrimp farming and hatchery activities; cold storage and trading of shrimps; and production and sale of shrimp and fish feeds. The company also provides fry and pet food products; shrimp and fish-based processed food products; and probiotic for shrimp medicines. In addition, it offers medicines for shrimp and fish. The company sells its products through Tokopedia and shopee official stores; and supplies to hotels, restaurants, and cafeterias in Indonesia. Further, the company sells its products under Fiesta Seafood, Shifudo, and Frosh brands. It also exports its products to the United States, Europe, and Japan. The company was formerly known as PT Central Proteinaprima Tbk and changed its name to PT Central Proteina Prima Tbk in June 2014. PT Central Proteina Prima Tbk was incorporated in 1980 and is headquartered in Jakarta Selatan, Indonesia.

CEO
Mr. Hendri Laiman
Employee
1.766
Address
Puri Matari 2 Building
Jakarta Selatan, 12920

PT Central Proteina Prima Tbk Executives & BODs

PT Central Proteina Prima Tbk Executives & BODs
# Name Age
1 Mr. Saleh Yu
Finance Director
70
2 Mr. Hendri Laiman
President Director
70
3 Mr. Ilphin Wunardi
Head of Internal Audit Division
70
4 Mr. Armand Ardika
Corporate Secretary
70
5 Mr. Aris Wijayanto
Director of Human Capital
70

PT Central Proteina Prima Tbk Competitors